Polaryx Therapeutics arrives at its May 22 results having shed nearly 59% of its value over the past month — a collapse that has reset the borrowing landscape entirely, even as the ORTEX short score remains firmly elevated.
The price action dominates the setup. The stock closed at $2.67 on May 15, down 21.7% on the day and 27% across the week — losses so sharp they dragged the RSI to an oversold 27. Yet short-side pressure in the lending market has actually eased considerably. Cost to borrow peaked above 300% in early April. It has since fallen to 29.4%, a steep decline that points to a far less aggressive short squeeze threat than the borrow market was pricing weeks ago. Availability has tightened recently — from above 350% in early April to roughly 128% now — but still sits in normal territory, leaving ample room for new shorts to enter if the print disappoints. Short shares outstanding climbed 24% in a single session on May 15 to around 440,000, though the float-adjusted figure is not calculable from available data.
The ORTEX short score of 69.5 tells a consistent story: shorts remain committed. That score has been range-bound between 60 and 70 for the better part of two weeks, suggesting neither a capitulation nor a material escalation in positioning. The March 24 earnings release produced a 13.8% single-day gain and a 37% five-day gain — a sharp positive reaction that illustrates how quickly a development-stage biotech can reverse when sentiment turns. The May print arrives in very different technical conditions: the stock has already given up most of those gains and sits closer to multi-month lows.
Ownership adds an important layer of context. The shareholder register is highly concentrated. Mstone Partners Hong Kong holds 47% of shares. A further cluster of Korean-affiliated individual and corporate holders accounts for a significant portion of the remaining register. Vanguard is the only large institutional name on the list, with a 3.7% stake added as recently as March 31. Rush University Medical Center holds just over 8%. This concentration means trading dynamics around the print could be dominated by a small number of participants rather than broad institutional re-positioning. The CFO's February purchase — 2,867 shares at $2.79 — was modest in dollar terms and predates the current selloff.
The May 22 print will test whether the pipeline narrative underpinning the March rally still holds water — or whether the subsequent 59% drawdown has already priced in something worse.
See the live data behind this article on ORTEX.
Open PLYX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
